JP2013521316A5 - - Google Patents

Info

Publication number

JP2013521316A5

JP2013521316A5 JP2012556409A JP2012556409A JP2013521316A5 JP 2013521316 A5 JP2013521316 A5 JP 2013521316A5 JP 2012556409 A JP2012556409 A JP 2012556409A JP 2012556409 A JP2012556409 A JP 2012556409A JP 2013521316 A5 JP2013521316 A5 JP 2013521316A5

Authority

JP

Japan

Prior art keywords

alkoxycarbonyl

acyl

optionally

group

alkyl

Prior art date

2011-03-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 15
• 150000001875 compounds Chemical class 0.000 claims 14
• 125000002252 acyl group Chemical group 0.000 claims 12
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 12
• 125000000217 alkyl group Chemical group 0.000 claims 12
• 239000008194 pharmaceutical composition Substances 0.000 claims 10
• -1 sulfonylamino, aminosulfonyl Chemical group 0.000 claims 10
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
• FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 claims 6
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 6
• 125000004442 acylamino group Chemical group 0.000 claims 6
• 125000004423 acyloxy group Chemical group 0.000 claims 6
• 125000003342 alkenyl group Chemical group 0.000 claims 6
• 125000003545 alkoxy group Chemical group 0.000 claims 6
• 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 6
• 125000004414 alkyl thio group Chemical group 0.000 claims 6
• 125000001118 alkylidene group Chemical group 0.000 claims 6
• 125000000304 alkynyl group Chemical group 0.000 claims 6
• 125000003710 aryl alkyl group Chemical group 0.000 claims 6
• 125000003118 aryl group Chemical group 0.000 claims 6
• 125000004104 aryloxy group Chemical group 0.000 claims 6
• 125000000753 cycloalkyl group Chemical group 0.000 claims 6
• 229910052736 halogen Inorganic materials 0.000 claims 6
• 150000002367 halogens Chemical group 0.000 claims 6
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
• 150000002825 nitriles Chemical group 0.000 claims 6
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
• SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical group NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims 6
• 125000001072 heteroaryl group Chemical group 0.000 claims 5
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
• MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 claims 4
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 4
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 4
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 4
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
• 201000010099 disease Diseases 0.000 claims 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
• JYYNAJVZFGKDEQ-UHFFFAOYSA-N 2,4-Dimethylpyridine Chemical compound CC1=CC=NC(C)=C1 JYYNAJVZFGKDEQ-UHFFFAOYSA-N 0.000 claims 2
• GYCPLYCTMDTEPU-UHFFFAOYSA-N 5-bromopyrimidine Chemical compound BrC1=CN=CN=C1 GYCPLYCTMDTEPU-UHFFFAOYSA-N 0.000 claims 2
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims 2
• 208000024172 Cardiovascular disease Diseases 0.000 claims 2
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Chemical group CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 2
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 2
• XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims 2
• 206010063837 Reperfusion injury Diseases 0.000 claims 2
• 229930003779 Vitamin B12 Natural products 0.000 claims 2
• 229910002091 carbon monoxide Inorganic materials 0.000 claims 2
• AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical class [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 2
• RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims 2
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Chemical group CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 2
• 150000004820 halides Chemical class 0.000 claims 2
• 125000005842 heteroatom Chemical group 0.000 claims 2
• 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
• 239000003446 ligand Substances 0.000 claims 2
• 239000000203 mixture Substances 0.000 claims 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
• 150000003839 salts Chemical class 0.000 claims 2
• 239000011715 vitamin B12 Substances 0.000 claims 2
• 235000019163 vitamin B12 Nutrition 0.000 claims 2
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
• 206010003210 Arteriosclerosis Diseases 0.000 claims 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
• 208000006029 Cardiomegaly Diseases 0.000 claims 1
• XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical group N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 1
• 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
• 206010020772 Hypertension Diseases 0.000 claims 1
• 206010021143 Hypoxia Diseases 0.000 claims 1
• 241000124008 Mammalia Species 0.000 claims 1
• 206010028980 Neoplasm Diseases 0.000 claims 1
• 206010038687 Respiratory distress Diseases 0.000 claims 1
• KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 1
• UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical group [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 1
• 206010052779 Transplant rejections Diseases 0.000 claims 1
• 230000004913 activation Effects 0.000 claims 1
• 239000002671 adjuvant Substances 0.000 claims 1
• 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
• 201000011510 cancer Diseases 0.000 claims 1
• CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
• 230000000747 cardiac effect Effects 0.000 claims 1
• 230000027288 circadian rhythm Effects 0.000 claims 1
• 235000000639 cyanocobalamin Nutrition 0.000 claims 1
• 239000011666 cyanocobalamin Substances 0.000 claims 1
• 229960002104 cyanocobalamin Drugs 0.000 claims 1
• 230000006378 damage Effects 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
• 230000007954 hypoxia Effects 0.000 claims 1
• 201000001881 impotence Diseases 0.000 claims 1
• 208000027866 inflammatory disease Diseases 0.000 claims 1
• 208000014674 injury Diseases 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 238000000034 method Methods 0.000 claims 1
• 210000001616 monocyte Anatomy 0.000 claims 1
• 208000010125 myocardial infarction Diseases 0.000 claims 1
• 210000000653 nervous system Anatomy 0.000 claims 1
• 230000004770 neurodegeneration Effects 0.000 claims 1
• 125000004043 oxo group Chemical group O=* 0.000 claims 1
• 229910052760 oxygen Inorganic materials 0.000 claims 1
• XRBCRPZXSCBRTK-UHFFFAOYSA-N phosphonous acid Chemical group OPO XRBCRPZXSCBRTK-UHFFFAOYSA-N 0.000 claims 1
• OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical group OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 claims 1
• 229910052698 phosphorus Inorganic materials 0.000 claims 1
• 229910000073 phosphorus hydride Inorganic materials 0.000 claims 1
• 230000002265 prevention Effects 0.000 claims 1
• 239000000651 prodrug Substances 0.000 claims 1
• 229940002612 prodrug Drugs 0.000 claims 1
• 230000005855 radiation Effects 0.000 claims 1
• 229910052707 ruthenium Inorganic materials 0.000 claims 1
• 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
• 150000003462 sulfoxides Chemical group 0.000 claims 1
• 229910052717 sulfur Inorganic materials 0.000 claims 1
• 208000011580 syndromic disease Diseases 0.000 claims 1
• 230000008736 traumatic injury Effects 0.000 claims 1